LearnGlossaryMarketStocksSuperinvestorsSign in

AMRX

Amneal Pharmaceuticals, Inc.

Healthcare · $6.5B market cap

Verdict

Share price

$20.30

close of Oct 3, 2026

Fair value

$10.56

Sticker Price

Payback Price

$4.22

buy price

Overpriced

AMRX is Overpriced: at $20.30 it trades 92% above its fair value of $10.56. Its buy price (Payback Price) is $4.22, 79% below today's price. Business quality is solid: 3 of 5 key numbers clear the 10% bar.

How we valued it

EV/EBITDA. Depreciation and interest costs distort its earnings, so the earnings-based methods gave an unrealistic answer. We value the whole business on its operating profit before those costs (EBITDA) instead, then adjust for debt and cash.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-5.4% a year✗
Equity per share growth-10.3% a year✗
Sales growth13.2% a year✓
Free cash flow growth12.7% a year✓
Return on invested capital10.1%✓

Follow AMRX

Get notified when it reaches its buy price of $4.22. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

BOYER ANDREW S

Executive Vice President · 2026-09-01

G-Gift

80,000 shares

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct…

Drug Manufacturers - Specialty & Generic

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works